• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献>>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

术前同期放化与单纯放疗局部晚期头颈部鳞癌的Ⅲ期临床研究

Phse Ⅲ study of preoperative concurrent chemoradiotherapy compared with preoperative radiotherapy alone in the treatment of locally advanced head and neck squamons cell carcinona

摘要目的 比较在局部晚期头颈部鳞癌治疗中术前同期放化疗是否优于术前单纯放疗。方法 2002-2008年间157例局部晚期头颈部鳞癌患者通过随机数字表法分入术前同期放化组(81例)和术前单放组(76例),化疗方案为顺铂30 mg/m2(1次/周),放疗DT50 Gy时原发灶疗效达到或者接近完全缓解以及未达完全缓解但患者拒绝手术者继续放疗至根治量70 Gy,原发灶疗效未达到或接近完全缓解者休息1个月后行手术治疗。放疗DT50 Gy时淋巴结未能达完全缓解和N3期患者行颈淋巴结清扫术。结果 随访率为98.1%,随访满5年者91例,同期放化组46例、单放组45例。头颈部鳞癌患者术前同期放化组和术前单放组的5年局部控制率、总生存率、无瘤生存率、无远处转移生存率分别为63%和50%(x2=0.40,P=0.528)、46%和38% (x2 =0.48,P=0.490)、41%和35%(x2=0.29,P=0.593)、76%和65%(x2=3.38,P=0.066)。下咽癌和喉癌患者术前同期放化组、术前单放组2年无远处转移生存率分别为88%、60% (x2 =5.99,P=0.014)。结论 在此化疗条件下,头颈部鳞癌术前同期放化疗与术前单纯放疗比较未能提高总生存率;下咽癌和喉癌中术前同期放化疗提高了无远处转移生存率。

更多

abstractsObjective To investigate the role of chemoradiotherapy in the preoperative radiotherapy for locally advanced head and neck squamous cell carcinoma. Methods From Sep. 2002 to Dec. 2008,totally 157 locally advanced head and neck squamous cell carcinoma (HNSCC) patients was assigned to preoperative concurrent chemoradiotherapy group ( n =81 ) or preoperative radiotherapy alone group ( n =76 ) randomly. The chemotherapy regimen was consisted of cisplatin 30 mg/m2, weekly. The radiotherapy in both groups was identical. The primary lesion will continue concurrent chemoradiotherapy or radiotherapy for those the tumor response was or nearly complete remission (CR) and those who refused surgery when evaluated at DT50 Gy, the others will receive surgery 1 month later if the tumor response was less than CR.For N3 patients, the planed neck dissection will be done. Results The follow up rate was 98. 1%, 91patients followed up more than 5 years, there were 46 in concurrent chemoradiotherapy group and 45 in radiotherapy alone group. The rate of 5-year local control, overall survival, disease free survival and distant metastasis-free survival for preoperative concurrent chemoradiotherapy group and preoperative radiotherapy alone group were 63% and 50% ( x2 =0. 40,P =0. 528), 46% and 38% ( x2 =0. 48,P =0. 490) ,41% and 35 ( x2 =0. 29, P =0. 593 ) ,76% and 65% ( x2 =3.38, P =0. 066 ) respectively. Subgroup analysis showed that the 2-years distant metastasis-free survival of preoperative concurrent chemoradiotherapy group and preoperative radiotherapy alone group were 88% and 60% ( x2 =5.99,P =0. 014). Conclusions Preoper -ative concurrent chemoraidotherapy with the regimen of cisplatin 30 mg/m2 weekly did not improve the overall survival for locally advanced HNSCC when compared with preoperative radiotherapy alone.Preoperative concurrent chemoradiotherapy improved the distant metastasis-free survival of locally advanced hypopharyngeal and laryngeal carcinoma.

More
广告
  • 浏览705
  • 下载285
中华放射肿瘤学杂志

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷